Target intelligence / Profile preview

Lymphocyte antigen 6 family member S (LY6S)

Target
LY6S
Molecular classification
GPI-anchored cell surface protein, Ly6/uPAR family, Single LU (Ly6/uPAR) domain protein, Other (not a classical receptor or enzyme)
01

Overview

Lymphocyte antigen 6 family member S (LY6S) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein in the Ly6/uPAR superfamily, characterized by a single LU domain structure. This IFN-inducible protein is encoded by the LY6S gene and displays multiple isoforms, primarily associated with the plasma membrane or secreted forms. LY6S is involved in immune signaling and is most highly expressed in immune-related human tissues, such as the spleen and in IFN-activated environments. Although specific physiological and pathological roles of LY6S are still emerging, related Ly6 family members are markers of immune cell subpopulations and are implicated in immune cell maturation, innate and adaptive immune responses, cell adhesion, and possibly in the regulation of inflammation and tumorigenesis. Dysregulation or overexpression of Ly6 proteins, including possible analogs of LY6S, has been linked to tumor immune resistance, notably in colorectal cancer, suggesting therapeutic potential as surface targets for immunotherapy or as biomarkers for patient stratification and monitoring.

Other names
Lymphocyte antigen 6SLY6SLY6S-iso1LY6S-iso2LY6S-iso3
02

Mechanism of action

Bispecific antibody (engages T cells to lyse tumor cells expressing target LY6 family member; context from LY6G6D studies and emerging strategy for LY6 family)

03

Biological functions

Immune responseSignal transductionPotential involvement in acetylcholine receptor signalingIFN (interferon)-inducible immune regulation
04

Disease associations

Cancer (notably colorectal cancer, immune resistance, tumor microenvironment)Inflammation (general for Ly6 family members, specific roles for LY6S unknown but probable)Infection (Ly6 family-wide, specific for LY6S less clear)
05

Safety considerations

Immune cell targeting (risk of off-tumor toxicity in immune-privileged tissues; inferred from general Ly6 targeting experience)Potential for cytokine release or broad immune effects due to roles in immune regulation (theoretical)
06

Interacting drugs

T-cell-dependent bispecific antibody (preclinical, anti-LY6G6D—not LY6S but highly relevant for Ly6 family therapeutics)

1 more in the full profile.

07

Biomarkers

LY6S protein expression (potential biomarker in cancers or IFN-activated tissues; strong evidence for related family member LY6G6D in colorectal cancer)

Beyond the preview

Go deeper on Lymphocyte antigen 6 family member S (LY6S).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lymphocyte antigen 6 family member S (LY6S).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call